https://aurionbiotech.com

Home - Aurion BiotechHome - Aurion Biotech Skip to content USA Japan Programs & Therapies Endothelial Disease Pipeline About Us Our Focus Leadership News Careers Resources Publications FAQ Clinical Trials Contact Us Programs & Therapies Endothelial Disease Pipeline About Us Our Focus Leadership News Careers Resources Publications FAQ Clinical Trials Contact Us Advancing First-in-Class Therapies for A Future Where Blindness Is Eliminated Aurion Biotech is pioneering innovative therapies to transform the treatment of  blindness and vision loss globally. Explore Our Science About Aurion Restoring vision. Transforming care. Scaling globally. At Aurion Biotech, we bring together global expertise in eye care, regenerative medicine, and drug development to address significant unmet needs in ophthalmology. We are united by a shared belief that treatments for blindness and vision loss should be available to patients and ophthalmologists everywhere. About Us The Global Need A global challenge shaped by limited treatments and growing demand. Blindness is a global burden that affects millions of patients and their loved ones.Our lead program addresses blindness caused by Corneal endothelial disease, which affects millions worldwide. Current surgical approaches depend on donor transplantation, limiting access and leaving a significant unmet need.We are developing therapies designed to broaden availability of treating blindness for both patients and ophthalmologists, simplify care, and address this gap on a global scale. Learn about endothelial disease 0 Completed Global Clinical Trials 0 + Patients Treated* 0 Regulatory Approval 0 + Surgeons Performing the Procedure* U.S. FDA Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) designation have been granted for this investigational program * As of 12/31/2025 Our Science Regenerative Cell Therapy A platform for regenerative therapies in ophthalmologyAurion Biotech is advancing a new class of regenerative medicines for the treatment of loss of vision and blindness.We develop advanced therapeutics that aim to improve patient outcomes, reduce treatment complications, enhance ophthalmologists’ ability to provide care, and optimize utilization of precious donated tissue.Our therapeutics development platform focuses on manufacturing scale to enable global patient reach, and quality testing to ensure consistent product performance. Lead program: Corneal Endothelial Cell Therapy (CECT)Aurion Biotech is advancing Corneal Endothelial Cell Therapy (CECT), a regenerative treatment that aims to replace lost or dysfunctional endothelial cells. Because endothelial cells cannot naturally regenerate, patients experience progressive vision loss. The cells delivered to patients are human corneal endothelial cells obtained from donated corneas. They do not contain any synthetic materials or artificial scaffold. The cells are not obtained by artificial reprogramming of cells that are foreign to the eye. Aurion’s cells are intended to repopulate the endothelium and help re-establish a corneal structure that is virtually indistinguishable from a healthy cornea with healthy fluid balance. This approach is being developed to: Provide minimally invasive care to patients Reduce reliance on donor tissue Streamline treatment delivery Support a potentially shorter and more comfortable recovery experience Expand global availability to advanced care AURN001 Our lead product is advancing this new class of therapy. AURN001 is a first-in-class combination therapy made from human, unmodified donor endothelial cells (neltependocel). The cells are delivered in a solution containing a rho-kinase inhibitor compound (Y-27632), which is readily eliminated by the patient’s body after it has helped the cells engraft. AURN001 is designed to restore corneal clarity by recreating a healthy corneal endothelium after diseased cells have been removed.AURN001 is being developed to: Rebuild a functional endothelial layer Provide a less-invasive alternative to graft-based keratoplasty Make more efficient use of donor tissue Explore Our AURN001 Our Science Regenerative Cell Therapy A platform for regenerative therapies in ophthalmologyAurion Biotech is advancing a new class of regenerative medicines for the treatment of loss of vision and blindness.We develop advanced therapeutics that aim to improve patient outcomes, reduce treatment complications, enhance ophthalmologists’ ability to provide care, and optimize utilization of precious donated tissue.Our therapeutics development platform focuses on manufacturing scale to enable global patient reach, and quality testing to ensure consistent product performance. Lead program: Corneal Endothelial Cell Therapy (CECT)Aurion Biotech is advancing Corneal Endothelial Cell Therapy (CECT), a regenerative treatment that aims to replace lost or dysfunctional endothelial cells. Because endothelial cells cannot naturally regenerate, patients experience progressive vision loss. The cells delivered to patients are human corneal endothelial cells obtained from donated corneas. They do not contain any synthetic materials or artificial scaffold. The cells are not obtained by artificial reprogramming of cells that are foreign to the eye. Aurion’s cells are intended to repopulate the endothelium and help re-establish a corneal structure that is virtually indistinguishable from a healthy cornea with healthy fluid balance. This approach is being developed to: Provide minimally invasive care to patients Reduce reliance on donor tissue Streamline treatment delivery Support a potentially shorter and more comfortable recovery experience Expand global availability to advanced care AURN001 Our lead product is advancing this new class of therapy. AURN001 is a first-in-class combination therapy made from human, unmodified donor endothelial cells (neltependocel). The cells are delivered in a solution containing a rho-kinase inhibitor compound (Y-27632), which is readily eliminated by the patient’s body after it has helped the cells engraft. AURN001 is designed to restore corneal clarity by recreating a healthy corneal endothelium after diseased cells have been removed.AURN001 is being developed to: Rebuild a functional endothelial layer Provide a less-invasive alternative to graft-based keratoplasty Make more efficient use of donor tissue U.S. FDA Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) designation have been granted for this investigational program Explore Our AURN001 Our Pipeline Advancing next-generation therapies that aim to transform the treatment of blindness and vision loss. VIEW PIPELINE Our Leadership Guided by global experts in ophthalmology, regenerative medicine, and cell therapy innovation. Meet our team Your Career Join a mission-driven organization shaping the future of sight restoration. explore careers latest updates Stay informed on our scientific progress, clinical milestones, and organizational news. In The News Aurion Biotech Appoints World Renowned Cornea Surgeon Marjan Farid, M.D.,to Chair Medical Advisory Board In The News Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months In The News Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer VIEW All Expanding the Reach of Every Donor Cornea Contact Us Aurion Biotech collaborates with clinicians, researchers, and partners committed to advancing the future of corneal treatments. Get in touch to learn more about our science, programs, and global mission Caution: New Drug – Limited by Federal (or United States) law to investigational use SeattleAurion Corporate Mailing Address117 E. Luisa Street, #561Seattle, WA 98102+1-206-210-0058 CambridgeAurion Biotech101 Cambridgepark Drive, 3rd FloorCambridge, MA 02140+1-857-639-4143 Tokyo Aurion Biotech Japan, LLC1-6-4 Hirakawacho, Chiyoda-ku,Tokyo 102-0093, Japan+81-3-6555-2218 Facebook-f Linkedin-in Back to top © 2026 Aurion Biotech. All rights reserved. Privacy Policy We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OKPrivacy Policyenusen-US1773674414https://aurionbiotech.com